Dawn Biopharma is an investment platform controlled by the KKR Healthcare Strategic Growth Fund II, established to own a diverse portfolio of companies committed to the development of innovative medicines and therapies. Dawn Biopharma aims to provide flexible capital to innovators and thought leaders across the life sciences ecosystem with a shared vision of delivering life-changing medicines to patients in need." title="" class="btn" data-container="body" data-html="true" data-id="250533" data-placement="top" data-toggle="popover" data-trigger="focus" style="color:#0077b5" tabindex="0" data-original-title="Dawn Biopharma"> 303 6,149
Activities
Technologies
Entity types
Location
Nordre Fasanvej 215, 2000 Frederiksberg, Denmark
Frederiksberg
Denmark
Employees
Scale: 11-50, 2-10
Estimated: 52
Engaged corporates
2Added in Motherbase
1 year, 8 months agoDevelopment of highly differentiated first-in-class antibody-drug conjugates (ADCs) for treatment of solid tumors.
Adcendo is a Danish clinical-stage biotech company headquartered in Copenhagen, dedicated to the development of highly differentiated First-In-Class Antibody-drug conjugates (ADCs) for treatment of solid tumors.
In November of 2024, the company announced the closing of a USD 135m series B financing round. With a total sum of USD 240m raised since 2021 and under the leadership of a highly experienced management team, Adcendo is moving forward a growing and highly differentiated pipeline of drug candidates into the clinic.
Read more at www.adcendo.com